Studies published in “Oncogene” have identified a highly important role for MUC1-C in activating a program of immune evasion in human cancer cells

The findings show that MUC1-C drives PD-L1 expression and represses effectors, such as interferon-gamma among others, of innate and adaptive immunity.  Targeting MUC1-C in human cancers thus represents a novel therapeutic strategy for reversing tumor-associated suppression of immune recognition and destruction.

DETAILS